Disse sidene inneholder informasjon kun beregnet pĂĄ helsepersonell

Du forlater nĂĄ hjernenett.no

Foreslåtte søkeord: Avflatning, Doseringsveileder, Interaksjoner, Brekspiprazol, Oppstart to injeksjoner, Antidepressiva, Bivirkninger

Digital produktpresentasjon av Abilify Maintena® (aripiprazol)

Videopresentasjonen gir en introduksjon av Abilify Maintena® (aripiprazol); et antipsykotikum i depotform som er indisert for vedlikeholdsbehandling av schizofreni hos voksne pasienter stabilisert med oral aripiprazol.

Les mer: Bivirkningsrapportering

Les mer: Abilify Maintena®felleskatalogtekst

 

NO-ABIM-0107-2022.04

NO-AM-2000055

 

  1. Abilify Maintena® SPC 10/2021 avsnitt 4.1.

  2. Abilify Maintena® SPC 10/2021, avsnitt 4.2

  3. Tiihonen J, Haukka J, Taylor M et al. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization  for Schizophrenia. Am J Psychiatry 2011;168:603–609)

  4. Abilify Maintena® SPC 10/2021, avsnitt 4.8

  5. Fleischhacker WW, Sanchez R, Perry PP et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135–144,

  6. Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44.

  7. Corell C, Citrome L, Haddadd PM et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016;77(suppl 3):1-24.

  8. Drake RE, Whitley R. Recovery and severe mental illness: description and analysis. Can J Psychiatry 2014; 59(5):236-42.

  9. Drake RE, Whitley R. Recovery and severe mental illness: description and analysis. Can J Psychiatry 2014; 59(5):236-42.

  10. Cechnicki A, Hanuszkiewicz I, Polczuk R. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia;Med Sci Monit, 2011; 17(5): CR277-283.

  11. Gutiérrez-Casares, Canas F, Rodriguez-Morales. A Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study CNS Spectrums 2010; 15: 327-337.

  12. Nickl-Jockschat, Schneider F, Pagel AD. Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients Eur Arch Psychiatry Clin Neurosci. 2011 Nov;261 Suppl 2:S166-71.

  13. Nazrallah Research Review. A More Rational Paradigm for Treating Schizophrenia September 2010. www.researchreview.co.nz.

  14. Tiihonen J, Haukka J, Taylor M. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia Am J Psychiatry 2011;168:603–609.

  15. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Cambridge Medicine). 4th ed. NY, USA: Cambridge University Press.

  16. Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884–897.

  17. Gorna K, Jaracz K, Jaracz J et al. Social functioning and quality of life in schizophrenia patients –relationship with symptomatic remission and duration of illness. Psychiatr Pol 2014;48:277–288.

  18. Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.  J Clin Psychiatry 2012;73:617–624.

  19. Kane JM,  Zhao C, Johnsons BR et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2015;18:145–154.

  20. Naber D, Hansen K, Forray C et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia Schizophren Res 2015;168: 498-504

  21. Citrome L. New second-generation long acting injectable antipsychotics for the treatment of Schizophrenia Expert Rev. Neurother. 2013;13(7): 767-783

  22. Falissard B, Sapin C, Loze Y et al. Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS) Int J Methods Psychiatr Res 2016;25:101–111.

  25. Abilify Maintena® SPC 10/2021, avsnitt 4.2.

  26. Abilify Maintena® SPC 10/2021, avsnitt 4.8.

  27. Abilify Maintena® SPC 10/2021, avsnitt 4.4.

Dato publisert 08.09.2022